Laura Sighinolfi

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A novel methodology for large-scale phylogeny partition

Mattia Prosperi, Massimo Ciccozzi, Iuri Fanti et al. · Nature Communications · 2011 · 136 citations · Full text

Life Sciences, Bioinformatics, Evolutionary Biology +14

Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART

Barbara Ensoli, Stefania Bellino, Antonella Tripiciano et al. · PLoS ONE · 2010 · 95 citations · Full text

Life Sciences, Immunology, Infectious Diseases +15

Coping Styles and Psychosocial-Related Variables in HIV-Infected Patients

Luigi Grassi, Roberto Righi, Laura Sighinolfi et al. · Psychosomatics · 1998 · 65 citations

Nursing, Psychology, Clinical Psychology +13

Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study

Roberta Gagliardini, Arturo Ciccullo, Alberto Borghetti et al. · Open Forum Infectious Diseases · 2018 · 64 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17